Therapeutic directions for Parkinson's disease
Identifieur interne : 000502 ( Main/Exploration ); précédent : 000501; suivant : 000503Therapeutic directions for Parkinson's disease
Auteurs : Ira Shoulson [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2010.
English descriptors
Abstract
The focus on disease‐modifying treatments and cures for Parkinson's disease (PD) has raised expectations for quantum leaps and overshadowed incremental gains that have been slowly achieved. Large multi‐center clinical trials such as DATATOP and PRECEPT keep on generating new knowledge that is relevant to clinical care as well as experimental therapeutics. The largely unforeseen relationship between circulating uric acid and the occurrence and progression of PD was developed and confirmed in these clinical trials. Systematic follow‐up of clinical trial cohorts after conclusion of the interventional phase provides added value that continues to inform about natural history, state and trait biomarkers, and genotype‐phenotype relationships. These efforts are enhanced by data mining, public reporting, and timely sharing of data and biological samples. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.22790
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic directions for Parkinson's disease</title><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:91FC1C8ECF0E643B2693982141F90538422E0031</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22790</idno><idno type="url">https://api.istex.fr/document/91FC1C8ECF0E643B2693982141F90538422E0031/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002900</idno><idno type="wicri:Area/Main/Curation">002552</idno><idno type="wicri:Area/Main/Exploration">000502</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Therapeutic directions for Parkinson's disease</title><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010">2010</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">S1</biblScope><biblScope unit="page" from="S152">S152</biblScope><biblScope unit="page" to="S154">S154</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">91FC1C8ECF0E643B2693982141F90538422E0031</idno><idno type="DOI">10.1002/mds.22790</idno><idno type="ArticleID">MDS22790</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>biomarkers</term><term>experimental therapeutics</term><term>uric acid</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The focus on disease‐modifying treatments and cures for Parkinson's disease (PD) has raised expectations for quantum leaps and overshadowed incremental gains that have been slowly achieved. Large multi‐center clinical trials such as DATATOP and PRECEPT keep on generating new knowledge that is relevant to clinical care as well as experimental therapeutics. The largely unforeseen relationship between circulating uric acid and the occurrence and progression of PD was developed and confirmed in these clinical trials. Systematic follow‐up of clinical trial cohorts after conclusion of the interventional phase provides added value that continues to inform about natural history, state and trait biomarkers, and genotype‐phenotype relationships. These efforts are enhanced by data mining, public reporting, and timely sharing of data and biological samples. © 2010 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000502 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000502 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:91FC1C8ECF0E643B2693982141F90538422E0031
|texte= Therapeutic directions for Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |